FLGT - Fulgent Genetics Inc logo

Fulgent Genetics Inc

FLGT

Fulgent Genetics offers clinical diagnostic services including molecular and genetic testing, anatomic pathology, and oncology tests. It also develops targeted cancer therapies and operates the Picture Genetics platform, serving healthcare providers and patients.

โš•๏ธ Healthcare NASDAQ Listed 2016 $ USD
$1,000 invested 10 years ago โ†’$2,251today

Score Overview

1 Year
Score
Net Growth-39.44%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth0.39%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score2.8
Net Growth-180.87%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth-67.36%
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-13x
Net Trend38%
Net Income Consistency
Rev Growth17x
Rev Trend70%
Revenue Consistency
All Time
Score
Net Growth-13x
Net Trend38%
Net Income Consistency
Rev Growth17x
Rev Trend70%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Fulgent Genetics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. FLGT does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 19.99โ€”
1 Year2025-10-22
$ 23.50-14.94%
5 Years2021-10-22
$ 84.06-76.22%
10 Years2016-10-21
$ 8.88125.11%
All Time2016-09-29
$ 9.18117.76%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 323M-$ 84M$ 257M
2025$ 322M-$ 60M$ 336M
2024$ 283M-$ 42M$ 258M
2023$ 289M-$ 167M$ 424M
2022$ 618M$ 143M$ 526M
2021$ 992M$ 104M$ 450M
2020$ 421M$ 214M$ 299M
2019$ 32M$ 28M
2018$ 21M-$ 4M$ 37M
2017$ 18M-$ 2M$ 41M
IPO2016$ 18M-$ 5M$ 46M
FLGT - Fulgent Genetics Inc logo

Fulgent Genetics Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 421M to $ 322M and net income went from $ 214M to -$ 60M. Revenue increased in 2 of those 5 years; net income in 2.

Between 2016 and 2025, revenue grew from $ 18M to $ 322M and net income went from -$ 5M to -$ 60M. Revenue increased in 70% of the years measured; net income in 38%.

Fulgent Genetics Inc currently holds a 5-year HDB Score of 2.8 out of 10. How the HDB Score is calculated.

Membership

Explore FLGT with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies